Meeting
2022 ASCO Annual Meeting
Taxanes plus cetuximab with or without platinum chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.
Authors
Khalil Saleh
Departemnt of Hematology, Gustave Roussy Cancer Campus, Villejuif, France
Khalil Saleh , Marie Vinches , Inga Safta , Emeline Guiard , Gregoire Marret , Roman Vion , Joel Guigay , Fran?Ois-R?Gis Ferrand , Florian Clatot , Christophe Le Tourneau , Audrey Rambeau , Esma Saada-Bouzid , Amaury Daste , Caroline Even
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6036)
DOI
10.1200/JCO.2022.40.16_suppl.6036
Abstract #
6036
Poster Bd #
28
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
First Author: Christine H. Chung
Poster
2024 ASCO Annual Meeting
Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.
First Author: Zahra Hamedi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Association between artificial intelligence (AI) -assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC): An observational cohort study.
First Author: Christopher Williams
Poster
2022 ASCO Annual Meeting
A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202.
First Author: Aarti K. Bhatia